Abstract: Over-expression of human epidermal growth factor receptor 2（HER-2） protein has long been established as a major negative prognostic factor of breast cancer. But the clinical landscape of HER-2 positive breast cancers has literally been transformed by the approval of antiHER2 agents， the establishment of neoadjuvant treatment and the accumulation of clinical experience. Neoadjuvant treatment is the standard care of locally advanced breast cancer， and its current role has expanded to the treatment of early breast cancer， increasing the rate of breastconserving surgery. Most large randomized trials comparing neoadjuvant treatment against identical adjuvant systemic therapy indicate that these strategies offer equivalent diseasefree survival（DFS） and overall survival（OS） outcomes. With the development of HER-2 targeted therapy and neoadjuvant treatment as a unique plat form for drug development， neoadjuvant therapy for HER-2 positive breast cancer is being increasingly studied. This review summarizes the recent advances made in the area of neoadjuvant therapy in HER2 positive breast cancer.